Propanc Biopharma, Inc. (PPCB)
USD 5.5
(-25.98%)
USD 5.5
(-25.98%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 | 927.18 Thousand USD | 73.02% |
| 2023 | 535.86 Thousand USD | -51.03% |
| 2022 | 1.09 Million USD | 61.44% |
| 2021 | 677.82 Thousand USD | -56.74% |
| 2020 | 1.56 Million USD | -8.21% |
| 2019 | 1.7 Million USD | -63.95% |
| 2018 | 4.73 Million USD | 38.7% |
| 2017 | 3.41 Million USD | 214.96% |
| 2016 | 1.08 Million USD | -36.79% |
| 2015 | 1.71 Million USD | 350.53% |
| 2014 | 380.5 Thousand USD | 1063.46% |
| 2013 | 32.7 Thousand USD | -56.29% |
| 2012 | 74.82 Thousand USD | 56782.58% |
| 2011 | -132.00 USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | 687.34 Thousand USD | 28.27% |
| 2024 Q3 | 794.03 Thousand USD | -16.09% |
| 2024 Q4 | 927.18 Thousand USD | 16.77% |
| 2024 Q2 | 946.26 Thousand USD | 37.67% |
| 2023 Q3 | 587.43 Thousand USD | -30.83% |
| 2023 Q1 | 995.72 Thousand USD | -9.01% |
| 2023 FY | 535.86 Thousand USD | -51.03% |
| 2023 Q2 | 849.29 Thousand USD | -14.71% |
| 2023 Q4 | 535.86 Thousand USD | -8.78% |
| 2022 Q1 | 592.17 Thousand USD | -12.64% |
| 2022 FY | 1.09 Million USD | 61.44% |
| 2022 Q4 | 1.09 Million USD | 9.73% |
| 2022 Q3 | 997.27 Thousand USD | 4.66% |
| 2022 Q2 | 952.85 Thousand USD | 60.91% |
| 2021 Q2 | 1.25 Million USD | 19.8% |
| 2021 Q1 | 1.05 Million USD | -32.89% |
| 2021 FY | 677.82 Thousand USD | -56.74% |
| 2021 Q4 | 677.82 Thousand USD | -32.21% |
| 2021 Q3 | 999.94 Thousand USD | -20.62% |
| 2020 Q1 | 2.54 Million USD | 48.94% |
| 2020 Q2 | 3.01 Million USD | 18.47% |
| 2020 Q3 | 2.75 Million USD | -8.47% |
| 2020 FY | 1.56 Million USD | -8.21% |
| 2020 Q4 | 1.56 Million USD | -43.16% |
| 2019 FY | 1.7 Million USD | -63.95% |
| 2019 Q3 | 2.01 Million USD | -26.16% |
| 2019 Q2 | 2.72 Million USD | -27.75% |
| 2019 Q1 | 3.77 Million USD | -20.29% |
| 2019 Q4 | 1.7 Million USD | -15.21% |
| 2018 FY | 4.73 Million USD | 38.7% |
| 2018 Q3 | 4.56 Million USD | 5.93% |
| 2018 Q2 | 4.3 Million USD | -4.56% |
| 2018 Q1 | 4.51 Million USD | 32.23% |
| 2018 Q4 | 4.73 Million USD | 3.76% |
| 2017 Q1 | 523.95 Thousand USD | -51.65% |
| 2017 Q2 | 1.78 Million USD | 240.37% |
| 2017 Q3 | 2.64 Million USD | 48.29% |
| 2017 Q4 | 3.41 Million USD | 29.06% |
| 2017 FY | 3.41 Million USD | 214.96% |
| 2016 Q1 | 2.07 Million USD | 21.2% |
| 2016 FY | 1.08 Million USD | -36.79% |
| 2016 Q4 | 1.08 Million USD | 326.88% |
| 2016 Q3 | -477.63 Thousand USD | -160.95% |
| 2016 Q2 | 783.59 Thousand USD | -62.29% |
| 2015 Q1 | 417.52 Thousand USD | 9.73% |
| 2015 FY | 1.71 Million USD | 350.53% |
| 2015 Q2 | 488.89 Thousand USD | 17.09% |
| 2015 Q4 | 1.71 Million USD | 71.86% |
| 2015 Q3 | 997.51 Thousand USD | 104.04% |
| 2014 Q1 | -12.85 Thousand USD | -139.1% |
| 2014 FY | 380.5 Thousand USD | 1063.46% |
| 2014 Q4 | 380.5 Thousand USD | 404.27% |
| 2014 Q3 | 75.45 Thousand USD | 77.31% |
| 2014 Q2 | 42.55 Thousand USD | 430.99% |
| 2013 Q4 | 32.88 Thousand USD | -12.54% |
| 2013 FY | 32.7 Thousand USD | -56.29% |
| 2013 Q3 | 37.59 Thousand USD | 0.08% |
| 2013 Q2 | 37.56 Thousand USD | 138.8% |
| 2013 Q1 | 15.73 Thousand USD | -78.97% |
| 2012 Q3 | 103.68 Thousand USD | 254.07% |
| 2012 Q4 | 74.82 Thousand USD | -27.84% |
| 2012 FY | 74.82 Thousand USD | 56782.58% |
| 2012 Q2 | 29.28 Thousand USD | 0.0% |
| 2011 Q4 | -132.00 USD | 0.0% |
| 2011 FY | -132.00 USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1310.00 USD | 70877.557% |
| Arch Therapeutics, Inc. | 5.64 Million USD | 83.585% |
| Evofem Biosciences, Inc. | 42.79 Million USD | 97.833% |
| Nascent Biotech, Inc. | -249.62 Thousand USD | 471.439% |
| Rebus Holdings, Inc. | 305 Thousand USD | -203.995% |
| Santhera Pharmaceuticals Holding AG | -6.3 Million USD | 114.707% |
| Qrons Inc. | 351.42 Thousand USD | -163.835% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 622.36 Thousand USD | -48.978% |
| Northwest Biotherapeutics, Inc. | 43.43 Million USD | 97.865% |
| ProtoKinetix, Incorporated | -20.4 Thousand USD | 4643.248% |
| Skye Bioscience, Inc. | -5.72 Million USD | 116.206% |
| Eiger BioPharmaceuticals, Inc. | 15.76 Million USD | 94.118% |
| Nanobac Pharmaceuticals, Incorporated | 4.11 Million USD | 77.485% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | -130.73% |
| SQZ Biotechnologies Company | -36.23 Million USD | 102.559% |
| Intellipharmaceutics International Inc. | 2.24 Million USD | 58.649% |
| Mesoblast Limited | 55.85 Million USD | 98.34% |
| Marizyme, Inc. | 18.56 Million USD | 95.007% |
| Genus plc | 190.6 Million USD | 99.514% |
| VioQuest Pharmaceuticals, Inc. | 2.23 Million USD | 58.531% |
| Pharming Group N.V. | 109.8 Million USD | 99.156% |
| Therapeutic Solutions International, Inc. | 860.24 Thousand USD | -7.782% |
| CNBX Pharmaceuticals Inc. | 1.21 Million USD | 23.618% |
| Nymox Pharmaceutical Corporation | 680 Thousand USD | -36.351% |
| ContraFect Corporation | -6.02 Million USD | 115.386% |
| PsyBio Therapeutics Corp. | 134.63 Thousand USD | -588.646% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.15 Million USD | 19.754% |
| IMV Inc. | 7.67 Million USD | 87.912% |
| AXIM Biotechnologies, Inc. | 5.5 Million USD | 83.148% |
| MultiCell Technologies, Inc. | 90.04 USD | -1029649.0% |
| ONE Bio Corp. | 9.04 Million USD | 89.744% |
| Accustem Sciences Inc. | -733.97 Thousand USD | 226.323% |
| RVL Pharmaceuticals plc | 12.94 Million USD | 92.838% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 1.36 Million USD | 32.222% |
| Q BioMed Inc. | 4.06 Million USD | 77.163% |
| Emmaus Life Sciences, Inc. | 30.55 Million USD | 96.965% |
| Mosaic ImmunoEngineering Inc. | 1 Million USD | 7.991% |
| Biomind Labs Inc. | 711.4 Thousand USD | -30.332% |
| American Oriental Bioengineering, Inc. | 60.54 Million USD | 98.469% |
| Provectus Biopharmaceuticals, Inc. | 1.99 Million USD | 53.627% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 12.8 Million USD | 92.76% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | -157.759% |
| THC Farmaceuticals, Inc. | 139.8 Thousand USD | -563.204% |
| Acro Biomedical Co., Ltd. | 19.86 Thousand USD | -4566.965% |
| Curative Biotechnology, Inc. | 2.2 Million USD | 57.893% |
| GB Sciences, Inc. | 1.74 Million USD | 46.937% |
| Alpha Cognition Inc. | -183.78 Thousand USD | 604.487% |
| HST Global, Inc. | 96.79 Thousand USD | -857.906% |
| CSL Limited | 10.52 Billion USD | 99.991% |
| Wesana Health Holdings Inc. | 206.21 Thousand USD | -349.617% |
| Halberd Corporation | 144.72 Thousand USD | -540.671% |
| Enzolytics Inc. | 981.65 Thousand USD | 5.549% |
| Agentix Corp. | 37.63 Thousand USD | -2363.889% |
| Resverlogix Corp. | 6.45 Million USD | 85.627% |
| Nuo Therapeutics, Inc. | -673.08 Thousand USD | 237.751% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | -2.02 Billion USD | 100.046% |
| Enzon Pharmaceuticals, Inc. | -47.01 Million USD | 101.972% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 86.887% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | 65.769% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | -8.83 Million USD | 110.489% |
| AVAX Technologies, Inc. | -5.9 Million USD | 115.706% |
| Zenith Capital Corp. | 10.06 Thousand USD | -9112.897% |
| Genscript Biotech Corporation | -1.06 Billion USD | 100.087% |
| Ember Therapeutics, Inc. | 200.43 Thousand USD | -362.594% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.38 Million USD | 61.141% |
| WPD Pharmaceuticals Inc. | 164.5 Thousand USD | -463.608% |
| Cotinga Pharmaceuticals Inc. | -18.31 Thousand USD | 5161.612% |
| Kadimastem Ltd | -253.1 Thousand USD | 466.329% |
| Helix BioMedix, Inc. | -2.57 Million USD | 136.077% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 20.27 Million USD | 95.427% |
| BioStem Technologies, Inc. | 4.47 Million USD | 79.267% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 201.25 Thousand USD | -360.704% |
| LadRx Corporation | -2.03 Million USD | 145.529% |
| Cell Source, Inc. | 9.23 Million USD | 89.957% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | -45.975% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | -45.975% |
| NovAccess Global Inc. | 2.17 Million USD | 57.439% |
| Affymax, Inc. | -5.59 Million USD | 116.566% |
| Itoco Inc. | 228.3 Thousand USD | -306.117% |
| Rasna Therapeutics, Inc. | 135.98 Thousand USD | -581.81% |
| Pathfinder Cell Therapy, Inc. | 4.95 Million USD | 81.295% |
| Mobile Lads Corp. | 484.23 Thousand USD | -91.476% |
| CytoDyn Inc. | 20.26 Million USD | 95.424% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | -647.00 USD | 143405.41% |
| NanoSphere Health Sciences Inc. | -9268.34 USD | 10103.798% |
| Alseres Pharmaceuticals, Inc. | 7.7 Million USD | 87.968% |
| SYBLEU INC | 473.71 Thousand USD | -95.727% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 4.45 Million USD | 79.197% |
| International Stem Cell Corporation | 2.59 Million USD | 64.201% |
| Bioxytran, Inc. | 1.89 Million USD | 51.173% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -1385.566% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | 57.486% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 3.43 Million USD | 73.0% |
| Adhera Therapeutics, Inc. | 8.55 Million USD | 89.16% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 772.6 Thousand USD | -20.007% |
| Innovation Pharmaceuticals Inc. | -1.25 Million USD | 174.175% |
| Neutra Corp. | 52.18 Thousand USD | -1676.661% |
| Windtree Therapeutics, Inc. | -2.48 Million USD | 137.251% |
| PureTech Health plc | -167.19 Million USD | 100.555% |
| Coeptis Therapeutics, Inc. | -244.9 Thousand USD | 478.585% |
| IXICO plc | -4.44 Million USD | 120.861% |
| IntelGenx Technologies Corp. | 13.21 Million USD | 92.986% |
| Gelesis Holdings, Inc. | 54.85 Million USD | 98.31% |
| CSL Limited | 10.52 Billion USD | 99.991% |
| Cellectis S.A. | -43.81 Million USD | 102.116% |